Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2392 - Circulating tumor cells as prognostic marker in ovarian carcinoma. Results from the ANTHALYA study.


09 Sep 2017


Poster display session


Translational Research;  Ovarian Cancer


Thibault de La Motte Rouge


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


T. de La Motte Rouge1, P. Cottu2, P. Pautier3, M. Provansal4, A. Floquet5, F. Selle6, M. Fabbro7, E. Kalbacher8, P. Follana9, A.F. Lesoin10, J. Medioni11, J. Dupin12, R. Ferri13, F. Bidard2, C. Dubot14, R. Rouzier15, F. Joly Lobbedez16

Author affiliations

  • 1 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 3 Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 4 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 5 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Medical Oncology, Groupe Hospitalier Diaconesse Croix Saint Simon, 75012 - PARIS/FR
  • 7 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 8 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 9 Medical Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 10 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 11 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 12 Statistics, ITM, 92650 - Boulogne Billancourt/FR
  • 13 Breast Gynaecological Cancers, ROCHE SAS, 92650 - Boulogne Billancourt/FR
  • 14 Medical Oncology, Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 15 Surgery, Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 16 Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR


Abstract 2392


Circulating tumor cells (CTC) are detected in 12–30% of advanced stage/relapsing ovarian carcinoma (OC). We evaluated the prognostic value of CTC counts among patients (pts) from the ANTHALYA trial, an open-label randomized phase II study evaluating addition of bevacizumab (Beva) to neoadjuvant carboplatin-paclitaxel (CP) in first line for pts with unresectable FIGO stage IIIc/IV ovarian, tubal or peritoneal adenocarcinoma.


We obtained CTC counts at baseline and before interval debulking surgery (IDS). A CTC threshold of ≥ 1 CTC/7.5 mL blood was considered as CTC+. We assessed the prognostic impact of CTCs on objective response rate (ORR), interval debulking surgery (IDS) rate, complete resection rate and progression-free survival (PFS), and explored their potential predictive impact on ORR and PFS according to bevacizumab therapy.


In 88 pts with an available CTC count at baseline, CTC+ pts (n = 29) had a 75.9% ORR (at IDS), vs 59.3% for pts with 0 CTC (n = 59): OR = 2.2 [0.8-5.8] (OR-adj=1.8 [0.8-5.8]). Respectively, 58.6% vs 66.1% were amenable to IDS and 55.2% vs 54.2% achieved a complete resection. Median PFS was 21 m [15.0-25.4] in CTC+ pts and 25.8 m [18.5-27.2] in pts with 0 CTC (HR = 1.5 [0.8-2.8] and HR-adj=1.7 [0.9-3.2]). CTC counts at IDS were available in 70 pts. At IDS, a complete resection was achieved in 66.7% of CTC+ pts (n = 6), and in 68.8% of pts with 0 CTC (n = 64). Exploration of the potential predictive impact of CTC is described in the table.Table:


Prognostic approach0 CTC at baseline (n = 59)CTC+ at baseline (n = 29)
ORR at IDS59.3%75.9%
Median PFS [95% CI]25.8 m [18.5-27.2]21.0 m [15.0-25.4]
Predictive approachBeva (n = 36)CP (n = 23)Beva (n = 17)CP (n = 12)
ORR at IDS61.1%56.5%82.4%66.7%
Median PFS [95% CI]25.8 [20.9-NE]20.3 [13.8-27.2]21.0 [15.0-30.6]20.6 [8.0-25.4]
Progression rate at M3636.1%56.5%52.9%83.3%


Baseline CTC counts in OC patients receiving neoadjuvant chemotherapy +/- bevacizumab carry dual prognostic information: CTC count at IDS do not add any information, CTC+ seems to be associated with a higher ORR, while 0 CTC count seems to be a prognostic factor with better PFS, in the whole population and among patients treated with bevacizumab.

Clinical trial identification


Legal entity responsible for the study





T. de La Motte Rouge: Consultancy work: AstraZeneca, Roche, MSD, Eisai, Sanofi Travel grants/meeting support: Roche, Novartis, Pfizer Corporate-sponsored research: Novartis. P. Cottu: Novartis, Roche, AstraZeneca, Nanostring, Pfizer. P. Pautier: Membership on an advisory board or board of directors: Roche: Travel grants/meeting support: Roche, Astra Zeneca, Pharmamar Corporate-sponsored research; Pharmamar, Novartis. A. Floquet: Membership on an advisory board or board of directors: Roche, AstraZeneca; Travel grants/meeting support: Roche, AstraZeneca. F. Selle: Consultancy work: Roche: Travel grants/meeting support: Roche, AstraZeneca, Pharmamar. M. Fabbro: Travel grants/meeting support: Roche. E. Kalbacher: Travel grants/meeting support: Roche, Pharmamar, GSK, Leo Pharma, AstraZeneca. P. Follana: Consultancy work: AstraZeneca, Novartis Travel grants/meeting support: Roche, AstraZeneca, Amgen. A.F. Lesoin: Employment: Centre Oscar Lambret, Lille. J. Medioni: Membership on an advisory board or board of directors: AstraZeneca, Pierre Fabre Consultancy work: Clovis Oncology; Travel grants/meeting support: Roche, Sanofi Aventis. J. Dupin: Employment: Roche. R-M. Ferri: Employment: Roche SAS. C. Dubot: Corporate-sponsored research: Roche. R. Rouzier: Membership on an advisory board or board of directors: Roche; Consultancy work: Roche; Travel grants/meeting support: Roche; Corporate-sponsored research: Roche. F. Joly Lobbedez: Consultancy work: AstraZeneca, Janssen, Tesaro, Roche, Sanofi, Novartis, Bristol-Myers Squib Travel grants/meeting support: Roche, Janssen, AstraZeneca, Tesaro Corporate-sponsored research: Astellas, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.